Vascular, Neurologic and Hormonal Abnormalities in Men with Persistent Sexual Dysfunction After Discontinuation of Finasteride

Persistent sexual side effects have been repeatedly reported in men after discontinuation of (DC) Finasteride (FIN), including ED, orgasmic dysfunction and/or genital anhedonia/anesthesia. Khera et al (2020) reported persistent physical sequelae including penile vascular changes in 25 men after DC FIN. The purpose of this study is to replicate Khera’s research findings in a larger […]

Gut Inflammation Induced by Finasteride Withdrawal: Therapeutic Effect of Allopregnanolone in Adult Male Rats

[P]revious observations in PFS patients and an experimental model showed alterations in gut microbiota populations, suggesting an inflammatory environment. To confirm this hypothesis, we…explored the effect of chronic treatment with finasteride…and its withdrawal…on the levels of steroids, neurotransmitters, pro-inflammatory cytokines and gut permeability markers in the colon of adult male rat. The obtained data demonstrate […]

Global online interest in finasteride sexual side effects

Prior literature has suggested that finasteride may negatively impact men’s sexual health. In 2011, the Food and Drug Administration (FDA) provided a warning on finasteride drug labels to incorporate sexual side effects such as reduced libido and erectile dysfunction. We aimed to evaluate global online interest in finasteride sexual side effects, their penetrance and variation, […]

Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin

A set of enduring conditions have been reported in the literature involving persistent sexual dysfunction after discontinuation of serotonin reuptake inhibiting antidepressants, 5 alpha-reductase inhibitors and isotretinoin. OBJECTIVE: To develop diagnostic criteria for post-SSRI sexual dysfunction (PSSD), persistent genital arousal disorder (PGAD) following serotonin reuptake inhibitors, post-finasteride syndrome (PFS) and post-retinoid sexual dysfunction (PRSD). METHODS: […]

How routine pharmacovigilance failed to identify finasteride’s persistent sexual side effects

When confronted with data that their product could cause persistent erectile dysfunction, the Risk Management Safety Team at Merck, in 2009, had the opportunity to take further action to sort out the issue. Realizing that many adverse event reports lacked adequate information, the team could have recommended conducting additional rigorous prospective studies on finasteride to […]

Differential Gene Expression in Post-Finasteride Syndrome Patients

This study is the first to consider gene expression differences in men with PFS in explaining the etiology of this condition. Given gene expression per se is not mechanistic and does not imply causality, experiments with downstream processes of protein expression and activity should be undertaken to provide mechanistic data and clarify the results of […]

Risk of Depression Associated With Finasteride Treatment

Crude pooled rates of depressive symptoms with versus without finasteride were 3.33% versus 2.54%; random-effects meta-analysis yielded an odds ratio of 2.14. In addition, risk of suicidal ideation or behavior was greater with versus without finasteride (21.2% vs 14.0%), and risk of sustained sexual dysfunction was high (60.1%). The findings support a growing impression that […]

Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride

In this pharmacovigilance case-noncase study, significant RORs of suicidality and psychological adverse events were associated with finasteride use in patients younger than 45 years who used finasteride for alopecia. The sensitivity analyses suggest that these disproportional signals of adverse events may be due to stimulated reporting and/or younger patients being more vulnerable to finasteride’s adverse […]